Recently, Xiamen University and the Scripps Research Institute have published a major research paper on Hecolin®, a commercial hepatitis E virus (HEV) vaccine. It is worth noting that the HEV vaccine used is the world's first HEV vaccine jointly developed by Xiamen University and Yangshengtang Wantai Biopharm, which is also the only HEV vaccine available on the market so far.
Researchers at Xiamen University began the research on HEV vaccine in 1998 and successfully launched the world's first HEV vaccine, Hecolin®, in 2012. The vaccine has not only served the domestic market, but also received extensive attention from the international community after its successful marketing.
